CORRECTING and REPLACING — Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat … – GlobeNewswire (press release)
|
CORRECTING and REPLACING — Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat …
GlobeNewswire (press release) Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced the submission of its Phase I/II clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1, the Company's DNA-based immunotherapy for … |
